Dr. Kalish brings 30 years’ experience as a drug hunter and leader in medicinal chemistry, CMC, project leadership and the preclinical/early clinical development of drug candidates. He consults for start-up biotech companies as Kalish Biopharma Consulting. Previously he was a co-founder of Cardioxyl Pharmaceuticals and served as Senior Vice President, Chemistry and Pre-Clinical Development until acquisition by Bristol-Myers Squibb in December 2015 for $300 mil upfront. Prior to joining Cardioxyl, Dr. Kalish held senior research management roles at biopharmaceutical companies including Idun Pharmaceuticals, Agouron Pharmaceuticals and Guilford Pharmaceuticals where he served as Senior Director of Medicinal Chemistry.

Dr. Kalish is an inventor on numerous issued US patents and co-inventor of multiple compounds that have advanced into clinical trials including Viracept™, a marketed HIV protease inhibitor. Dr. Kalish earned his Ph.D. in organic chemistry from Penn State University and his B.S. from Rutgers University.